The following is a complete listing of the claims indicating the current status of each claim and including amendments currently entered.

- 1 18 (Withdrawn)
- 19 25 (Canceled)
- 26 32 (Withdrawn)
- 33. (Canceled) A method according to claim 30, wherein the chelator is TPEN or a TPEN derivative.
- 34. (New) A composition for inhibiting at least one of tumor cellular invasion and tumor metastasis, the composition comprising:
 - a. an effective amount of at least one of:
 - i. NNN'N'-Tetrakis- (2-pyridyl methyl)-ethylenediamine (TPEN); and
 - ii. a TPEN derivative; and
 - b. a pharmaceutically acceptable carrier.
- 35. (New) A composition according to claim 34, wherein the TPEN is in a concentration of 0.001-100 micromolar.
- 36. (New) A composition according to claim 34, wherein said TPEN has a higher affinity for divalent zinc ions than for other divalent metallic ions.
- 37. (New) A composition according to claim 34, wherein said composition is lipid soluble.
- 38. (New) A composition according to claim 34, wherein said TPEN has a greater ion affinity for zinc (Zn²⁺) ions than for Fe²⁺ ions.
- 39. (New) A composition according to claim 38, wherein said TPEN has a greater ion affinity for Fe²⁺ ions than for Mn²⁺ ions.
- 40. (New) A composition according to claim 39, wherein said TPEN has a greater ion affinity for Mn²⁺ ions than for Ca²⁺ ions.
- 41. (New) A composition according to claim 40, wherein said TPEN has a greater ion affinity for Ca²⁺ ions than for Mg²⁺ ions.

US Pat. App. Ser. No. 10/550,681 September 26, 2005 Page 3 of 8

- 42. (New) A composition according to claim 34, wherein said TPEN derivative is selected from the group consisting of ethylendiamine, diethylenetriamine, triethylenetetramine, triethylenediamine, tetraethylenep entamine, aminoethylethanol amine, aminoethylpiperazine, pentaethylenehexamine, triethylenetetramine-hydrochloride, tetraethylenepentamine- hydrochloride, pentaethylenehexamine-hydrochloride, tetraethylpentamine, captopril, penicilamine and transition metal binding peptides.
- 43. (New) A composition according to claim 34, wherein said TPEN is complexed with a metal.
- 44. (New) A method for preventing at least one of tumor cellular invasion and tumor metastasis in a mammal, the method comprising administering an effective amount of at least one of:

NNN'N'-Tetrakis- (2-pyridyl methyl)-ethylenediamine (TPEN); and a TPEN derivative;

to said mammal.

- 45. (New) A method according to claim 44, wherein said TPEN prevents metastatic cellular invasion in said mammal.
- 46. (New) A method according to claim 44, wherein said TPEN prevents cancerous cell migration in said mammal.
- 47. (New) A method according to claim 44, wherein the TPEN is in a concentration of 0.001-100 micromolar.
- 48. (New) A method according to claim 44, wherein said TPEN selectively prevents capillary formation in tumor and cancerous cells in said mammal.
- 49. (New) A method according to claim 48, wherein said preventing capillary formation inhibits the spread of cancer in said mammal.
- 50. (New) A method according to claim 48, wherein said TPEN is lipid soluble.
- 51. (New) A method according to claim 44, wherein said TPEN has a higher affinity for divalent zinc ions than for other divalent metallic ions.
- 52. (New) A method according to claim 51, wherein said higher affinity enables normal physiological function in said mammal.

US Pat. App. Ser. No. 10/550,681 September 26, 2005 Page 4 of 8

- 53. (New) A method according to claim 44, wherein said method further prevents or treats a disease or disorder selected from the group consisting of: primary malignancy, carcinoma, Hodgkin's disease, lymphoma, a hematological disease, angiogenesis, vasculogenesis, tumor cellular invasion and tumor metastasis.
- 54. (New) A method according to claim 44, wherein said TPEN permeates across cell membranes.
- 55. (New) A method according to claim 42, wherein said TPEN is complexed with a metal to form a TPEN-metal complex.
- 56. (New) A method according to claim 44, wherein said TPEN derivative is selected from the group consisting of ethylendiamine, diethylenetriamine, triethylenetetramine, triethylenediamine, tetraethylenep entamine, aminoethylethanol amine, aminoethylpiperazine, pentaethylenehexamine, triethylenetetramine-hydrochloride, tetraethylenepentamine- hydrochloride, pentaethylenehexamine-hydrochloride, tetraethylpentamine, captopril, penicilamine and transition metal binding peptides.